Streetbeat News

Products Services

NVEI

Nuvei Corporation (NASDAQ:NVEI) has partnered with Scanco Software to enhance Scanco's new Invoice2Payment (i2PAY) solution, improving payment capabilities for warehouse and manufacturing operations.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:36 pm

TEM

Tempus AI has announced the publication of a validation study for its HLA-LOH investigational assay in npj Precision Oncology. The study demonstrates the detection of HLA loss of heterozygosity using Tempus' FDA-approved xT CDx assay, which offers prognostic and therapeutic opportunities for solid tumor patients.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:35 pm

PLSE

Pulse Biosciences has announced the treatment of the first two patients in a first-in-human feasibility study using its Nano-PFA Cardiac Surgery System for atrial fibrillation. The system is also enrolled in the FDA's Total Product Life Cycle Advisory Program.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:35 pm

FOXO

FOXO Technologies' subsidiary, Myrtle Recovery Centers, has received two full licenses from the Tennessee Department of Mental Health and Substance Abuse Services.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:34 pm

CYBR

SAP

CyberArk announced that SAP Enterprise Cloud Services will implement CyberArk's solutions to secure privileged access with zero standing privileges, enhancing client data protection and auditing.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:33 pm

CRL

OGEN

Oragenics Inc. (NYSE:OGEN) announced that its concussion drug, ONP-002, has cleared FDA-required cardiotoxicity testing, indicating it does not cause cardiotoxicity. The company is planning Phase 2 trials to assess the drug's safety and effectiveness. The stock was trading higher by 4.50% premarket.

Portfolio Pulse from Vandana Singh

August 08, 2024 | 12:30 pm

OGEN

Oragenics has announced that its product ONP-002 has a potential addressable market opportunity that includes an estimated 69 million concussions globally.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:30 pm

OGEN

Oragenics announced that its concussion drug, ONP-002, has successfully cleared FDA-required cardiotoxicity testing. This is a significant milestone for the company as it progresses in the development of this drug.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:30 pm

HCAT

Health Catalyst, Inc. (NASDAQ:HCAT) has announced an expanded partnership with Contexture to include technology and services support for Quality Health Network. Contexture is a nonprofit organization that facilitates health data interoperability in Arizona and Colorado.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:29 pm

APLS

Apellis Pharmaceuticals shares are trading higher following the announcement of positive topline results from the Phase 3 VALIANT study on systemic pegcetacoplan for treating C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:29 pm